TomoTherapy to Enhance Remote Service and Diagnostics Capabilities : Radiation Therapy Innovator to Deploy Questra IDM Application Suite™

Share Article

TomoTherapy Incorporated (NASDAQ: TOMO), maker of the Hi·Art® treatment system for advanced radiation therapy, today announced plans to enhance the remote service and diagnostics capabilities of its industry-leading customer support program.

News Image
We are delighted to be working with TomoTherapy as they take their customer service to the next level. Innovative companies, like TomoTherapy, are turning to remote, preemptive service as a means to deliver greater value to their customers.

In late 2008, TomoTherapy will pilot the Questra IDM (Intelligent Device Management) Application Suite, an auto-intelligent remote support solution from Questra Corporation. Phase I integration of this capability will provide TomoTherapy with the ability to remotely update Hi·Art system software and receive product performance information over a secure Internet connection to enhance overall user experience. In subsequent phases of implementation, the Questra-based solution is expected to offer Hi·Art users remote planning, plan review and quality assurance capabilities.

For two consecutive quarters, TomoTherapy has topped MD Buyline's user satisfaction rankings for radiation therapy manufacturers. According to Rich Springer, TomoTherapy's vice president of customer support, the partnership with Questra reinforces TomoTherapy's commitment to continuous improvement.

"Our customers expect the best in both treatment quality and customer service from TomoTherapy. Questra's device management solution will help us continue to deliver on these expectations. In addition to optimizing Hi·Art system uptime across our growing installed base, we expect to also realize a new level of operational efficiency."

Emil Wang, Questra CEO, added: "We are delighted to be working with TomoTherapy as they take their customer service to the next level. Innovative companies, like TomoTherapy, are turning to remote, preemptive service as a means to deliver greater value to their customers."

About Questra Corporation

Questra is leading the development and marketing of IDM solutions. Equipment manufacturers use the Questra IDM Application Suite, which proactively monitors and manages remote intelligent devices, to provide superior yet cost-effective support to their customers. Agfa Graphics, General Electric, Scientific Applications International Corporation (SAIC), and Waters, among other Fortune 1000 companies, have chosen Questra software as part of their corporate strategies to advance from reactive to proactive equipment service and support. For more information, visit http://www.questra.com.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms "plans", "will", "can" or "is expected to" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to gain customer acceptance, ability to complete development in a timely manner, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patty Kitowski
Visit website